Page 753 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

36. ASPARAGINASE 711

9. CONTRE-INDICATIONS
Femme enceinte ou qui allaite, insuffisance hépatique, pancréatite, hypersensibilité con-
nue au produit ou à un de ses composants, utilisation de phénytoïne à visée prophylac-
tique, vaccin contre la fièvre jaune.

BIBLIOGRAPHIE
HOP .P.K. et al., Crystalline L-asparaginase from Escherichia coli B, J. Biol. Chem., 1970,
245, 3708-3715.
MINTON N.P. et al., Nucleotide sequence of the Erwinia chrysanthemi NCPPB 1066
L-asparaginase gene, Gene, 1986, 46, 25-35.
BONTHRON D.T., L-Asparaginase Il of Escherichia coli K-12: cloning, mapping and
sequencing of the ansB gene, Gene, 1990, 91, 101-105.
SWAIN A.L. et al., Crystal structure of Escherichia coti L-asparaginase, an enzyme used
in cancer therapy, Proc. Nat/ Acad. Sei., États-Unis, 1993, 90, 1474-1478.
BLATTNER F.R. et al., The complete genome sequence of Escherichia coli K-12,
Science, 1997, 277, 1453-1474.
ETTINGER L.J. et al., Acute lymphoblastic leukemia : a guide to asparaginase and
pegaspargase therapy, Biodrugs, 1997, 7, 30-39.
ASSELIN B.L., The three asparaginases. Comparative pharmacological optimal use in
childhood leukemia, Adv. Exp. Med. Biol., 1999, 457, 621-629.
ESTLIN E.J. et al., The clinical and cellular pharmacology of vincristine, corticosteroids,
L-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute
lymphoblastic leukemia, Br. J. Haematol., 2000, 110, 780-790.
VIEIRA PINHEIRO J.P. et al., Use of PEG-asparaginase in the treatment of patients with
solid tumors, Cancer Chemother. Pharmacol., 2001, 48, 421-422.
OTTEN J. et al., The children leukemia group : 30 years of research and achievements,
Eur. J. Cancer, 2002, 38, S44-S49.